Colorectal cancer specialists review recent updates from BESPOKE-CRC evaluating the utilization of circulating tumor DNA for informing adjuvant therapy in patients with colorectal cancer.
Atezolizumab Combo Improves Survival in Metastatic CRC
Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
New HIV Guidelines Recommend Screening to Mitigate Anal Cancer Risk
Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.
Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions
Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
FDA Discourages Accelerated Approval of Botensilimab/Balstilimab Combo in R/R MSS CRC
The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.
Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC
Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.